microdosing of glp 1 Found Health Launches GLP-1 Program for Early Metabolic Dysfunction Microdosing" your GLP-1 is probably

[DOI] [Google Scholar] 239.Slingu M

Published data from the Phase 3b STRIDE trial reported that Ozempic 1 mg via subcutaneous (SC) injection once weekly improved maximum walking distance by 13% compared to placebo after 52 weeks

In fact, as MassHealth ends coverage for GLP-1s to treat weight loss, Medicare is going in the opposite direction

Conclusions GLP-1R agonist therapies are breakthrough medications for patients with T2D and can help them achieve weight loss, improve -cell function, and reduce a risk of causing hypoglycemia

Coverage also depends on your condition and certain criteria

Without meticulous data, you cannot determine whether each switch is producing benefit or just causing disruption